Second Primary Cancers After Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers.
cancer etiology
cancer incidence
hepatobiliary cancer
relative risk
second primary cancer
Journal
Clinical epidemiology
ISSN: 1179-1349
Titre abrégé: Clin Epidemiol
Pays: New Zealand
ID NLM: 101531700
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
05
2021
accepted:
28
06
2021
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
epublish
Résumé
Second primary cancers (SPCs) are important clinically as they may negatively influence patient survival and they may tell about therapeutic side effects and general causes of cancer. Population-based literature concerning SPCs after hepatobiliary cancers is limited and here we assess risks of SPCs after hepatocellular cancer (HCC), and cancers of the gallbladder, bile ducts and ampulla of Vater. In reverse order, we consider the risk of hepatobiliary cancers as SPCs after any cancer. We used standardized incidence ratios (SIRs) to estimate bidirectional relative risks of subsequent cancers associated with hepatobiliary cancers. Cancer diagnoses were obtained from the Swedish Cancer Registry from years 1990 through 2015. We identified 9997 primary HCCs, 1365 gallbladder cancers and 4721 bile duct cancers. After HCC, risks of four SPCs were increased: gallbladder (SIR = 4.38; 95% confidence interval 1.87-8.67), thyroid (4.13; 1.30-9.70), kidney (2.92; 1.66-4.47) and squamous cell skin (1.55; 1.02-2.26) cancers. In reverse order, HCC as SPC, in addition to the above cancers, associations included upper aerodigestive tract, esophageal, small intestinal and bladder cancers and non-Hodgkin lymphoma. For gallbladder and bile duct cancers, associations were found with small intestinal and pancreatic cancers. The results suggested that HCC is associated with two types of SPC, one related to shared environmental risk factors, such as alcohol, exemplified by upper aerodigestive tract and esophageal cancer, and the other related to immune dysfunction, exemplified by squamous cell skin cancer. SPCs associated with gallbladder and bile duct cancers suggest predisposition to mutations in the mismatch repair gene MLH1.
Sections du résumé
BACKGROUND
BACKGROUND
Second primary cancers (SPCs) are important clinically as they may negatively influence patient survival and they may tell about therapeutic side effects and general causes of cancer. Population-based literature concerning SPCs after hepatobiliary cancers is limited and here we assess risks of SPCs after hepatocellular cancer (HCC), and cancers of the gallbladder, bile ducts and ampulla of Vater. In reverse order, we consider the risk of hepatobiliary cancers as SPCs after any cancer.
METHODS
METHODS
We used standardized incidence ratios (SIRs) to estimate bidirectional relative risks of subsequent cancers associated with hepatobiliary cancers. Cancer diagnoses were obtained from the Swedish Cancer Registry from years 1990 through 2015.
RESULTS
RESULTS
We identified 9997 primary HCCs, 1365 gallbladder cancers and 4721 bile duct cancers. After HCC, risks of four SPCs were increased: gallbladder (SIR = 4.38; 95% confidence interval 1.87-8.67), thyroid (4.13; 1.30-9.70), kidney (2.92; 1.66-4.47) and squamous cell skin (1.55; 1.02-2.26) cancers. In reverse order, HCC as SPC, in addition to the above cancers, associations included upper aerodigestive tract, esophageal, small intestinal and bladder cancers and non-Hodgkin lymphoma. For gallbladder and bile duct cancers, associations were found with small intestinal and pancreatic cancers.
CONCLUSION
CONCLUSIONS
The results suggested that HCC is associated with two types of SPC, one related to shared environmental risk factors, such as alcohol, exemplified by upper aerodigestive tract and esophageal cancer, and the other related to immune dysfunction, exemplified by squamous cell skin cancer. SPCs associated with gallbladder and bile duct cancers suggest predisposition to mutations in the mismatch repair gene MLH1.
Identifiants
pubmed: 34377034
doi: 10.2147/CLEP.S318737
pii: 318737
pmc: PMC8349530
doi:
Types de publication
Journal Article
Langues
eng
Pagination
683-691Informations de copyright
© 2021 Zheng et al.
Déclaration de conflit d'intérêts
A.H. is a shareholder in Targovax ASA; also is an employee and shareholder in TILT Biotherapeutics Ltd. Other authors declared no conflict of interest.
Références
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32209603
Liver Int. 2013 Apr;33(4):616-23
pubmed: 23331767
Eur J Cancer. 2010 Mar;46(4):765-81
pubmed: 20116997
Eur J Epidemiol. 2016 Apr;31(4):337-50
pubmed: 27209009
Cancer Med. 2020 Nov;9(21):8258-8265
pubmed: 32960498
Int J Cancer. 2019 Feb 15;144(4):707-717
pubmed: 30155920
J Clin Endocrinol Metab. 2005 Oct;90(10):5747-53
pubmed: 16030170
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604
pubmed: 31439937
Immunity. 2019 Jul 16;51(1):15-26
pubmed: 31315033
BJS Open. 2020 Feb;4(1):109-117
pubmed: 32011814
World J Gastrointest Oncol. 2015 May 15;7(5):30-46
pubmed: 25987950
Front Immunol. 2020 Aug 27;11:1915
pubmed: 32973794
Int J Cancer. 2017 Mar 1;140(5):1091-1101
pubmed: 27870055
Genes (Basel). 2019 Jun 26;10(7):
pubmed: 31247975
Cancer Lett. 2015 Dec 1;369(1):152-66
pubmed: 26319898
Clin Gastroenterol Hepatol. 2014 Jun;12(6):1038-45.e7
pubmed: 24246767
J Transl Autoimmun. 2020 Jun 01;3:100058
pubmed: 32743538
J Natl Cancer Inst. 2000 Jul 19;92(14):1159-64
pubmed: 10904089
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Nat Rev Clin Oncol. 2013 May;10(5):289-301
pubmed: 23529000
Nat Rev Nephrol. 2010 Sep;6(9):511-9
pubmed: 20736984
Pathol Res Pract. 2020 Sep;216(9):153098
pubmed: 32825964
Alcohol Clin Exp Res. 2020 Feb;44(2):384-403
pubmed: 31854001
Int J Cancer. 2006 May 1;118(9):2285-92
pubmed: 16342146
Acta Oncol. 2018 Apr;57(4):440-455
pubmed: 29226751
Urol Oncol. 2020 Jun;38(6):590-598
pubmed: 32057596
Gut. 2003 Apr;52(4):592-6
pubmed: 12631675
Front Oncol. 2019 Aug 13;9:762
pubmed: 31456946
Eur J Cancer Prev. 2015 Mar;24 Suppl 1:S1-S63
pubmed: 25599121
Int J Cancer. 2012 Nov 1;131(9):2085-93
pubmed: 22307919
PLoS One. 2020 Oct 20;15(10):e0240794
pubmed: 33079961
Int J Cancer. 2015 Aug 15;137(4):903-10
pubmed: 25604005
J Natl Cancer Inst. 2000 Jul 19;92(14):1114-5
pubmed: 10904078
Gut. 2018 Jul;67(7):1306-1316
pubmed: 28754778
Pathol Oncol Res. 2015 Jul;21(3):509-25
pubmed: 25618479
Clin Exp Hepatol. 2019 May;5(2):93-102
pubmed: 31501784
Lancet Oncol. 2015 Jan;16(1):36-46
pubmed: 25467404
Clin Epidemiol. 2020 Aug 06;12:857-864
pubmed: 32821171
World J Hepatol. 2020 Aug 27;12(8):475-484
pubmed: 32952874
Thyroid. 2013 Jul;23(7):879-84
pubmed: 23421548
JGH Open. 2020 Apr 15;4(3):351-359
pubmed: 32514436
Int J Cancer. 1995 Jan 17;60(2):183-9
pubmed: 7829213
Cancer Treat Res. ;168:101-20
pubmed: 29206367